Friday 6 November 2026 Export LKFT’s income statement to Excel — free account

Lakefront Biotherapeutics - Sponsored ADR

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.

Revenue: −95.4%
EPS: +198.9%
Free cash flow: +18.2%

Quarter to June 2026, against a year earlier

Operating cash flow growth 3 yrs

33.47 0.09 −0.27%

Follow LKFT

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −15.3×
Dividend yield: —
F-score: 6/9
Altman Z: 8.43
Beneish M: 0.34
Dividend safety: n/a

Overview

Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Lakefront Biotherapeutics - Sponsored ADR (LKFT) trades at a P/S ratio of 7.9×. Over the past ten years it has ranged from 0.0× (December 2015) to 64.1× (January 2018); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LKFT/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Lakefront Biotherapeutics - Sponsored ADR P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LKFT/metrics/ps-ratio">Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	4.9×	50.23%
FY2024	3.3×	(30.16%)
FY2023	4.7×	(14.31%)
FY2022	5.5×	(13.06%)
FY2021	6.3×	(40.80%)
FY2020	10.6×	(10.46%)
FY2019	11.9×	(6.75%)
FY2018	12.7×	(74.73%)
FY2017	50.4×	6.99%
FY2016	47.1×	41.91%

Period	P/S ratio	Change
Mar 2026	7.0×	85.35%
Mar 2025	3.8×	(2.29%)
Mar 2024	3.9×	(0.87%)
Sep 2023	3.9×	(14.01%)
28 more quarters	Free account

Against its own ten years

Low 0.0× High 64.1×

Ten-year median 6.9×

Current reading's percentile 51

Company	P/S ratio
VERA Vera Therapeutics, Inc. compare	n/m
BHVN Biohaven Ltd. compare	2.1×
AUPH Aurinia Pharmaceuticals Inc compare	6.7×
LKFT Lakefront Biotherapeutics - Sponsored ADR	7.9×
VCEL Vericel Corporation compare	8.1×
SEPN Septerna, Inc. compare	21.8×
PVLA Palvella Therapeutics, Inc. compare	54.1×
ZYME Zymeworks Inc. compare	56.8×
IMNM Immunome, Inc. compare	162×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on LKFT

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on LKFT

Stockrow Weekly